The nation of Zimbabwe has rejected a substantial American healthcare agreement worth $367m (£272m) spanning five years because of Washington's request for confidential biological samples.
This move was revealed after a internal memorandum from December was leaked, indicating that President Emmerson Mnangagwa felt the arrangement was "skewed".
A government spokesperson later explained that the US was seeking genetic material for scientific study and profit but was unwilling to share the benefits from future treatments.
"We are forced to start the difficult and regrettable task of ending our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had donated over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has called for continued talks to secure a deal suitable to all parties so the country's vital HIV treatment initiative can be sustained.
Broader Implications
This rejection follows a similar situation in Kenya, where a high court halted a related deal with the US following legal challenges were filed about the security of Kenyans' health data.
Since returning to the presidency recently, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had administered aid for the American government, but Trump claimed its spending was "wasteful" and his government was pursuing government-to-government deals to boost openness and accountability.
Based on statements, Sixteen African countries have to date agreed to these new health pacts, constituting over $18.3bn of fresh investment.
Details of the Declined Deal
The funds for Zimbabwe would have supported "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this cooperation could have provided significant benefits for the people of Zimbabwe, especially the 1.2 million presently receiving HIV treatment through US-supported initiatives," Tremont said.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"Zimbabwe was being asked to surrender its biological resources and data for a long time, without any corresponding guarantee of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that shared data," Mangwana explained.
"Effectively, our nation would supply the basic resources for medical research with no certainty that the end products would be available to our citizens should a future health crisis arise."
National Interest and International Frameworks
Mangwana further noted that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were undermining systems previously established via the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme created to manage future global health emergencies.
"This system is designed to ensure that when a country contributes its samples, the benefits – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the capability to create them."
Zimbabwe's reservations over the US deal "must not be interpreted as hostility towards the US," he added.
"We encourage further discussions with our US partners on how subsequent collaboration could be arranged in a way that honours the independence and interests of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it recognised the official position, but suggested that negotiations need to persist considering a large portion of the nation's HIV programmes relied on external financing.
"If specific concerns exist, including those involving data governance or agreement terms, these can often be resolved via technical clarification and mutually agreed protections," the group said.
The situation underscores the ongoing debate between accepting crucial international aid and safeguarding a country's data in an ever more data-driven world.